Skip to main content
Erschienen in: Heart Failure Reviews 4/2017

03.06.2017

Role of PET to evaluate coronary microvascular dysfunction in non-ischemic cardiomyopathies

verfasst von: Paco E. Bravo, Marcelo F. Di Carli, Sharmila Dorbala

Erschienen in: Heart Failure Reviews | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Coronary microvascular dysfunction (CMD) can result from structural and functional abnormalities at the intramural and small coronary vessel level affecting coronary blood flow autoregulation and consequently leading to impaired coronary flow reserve. CMD often co-exists with epicardial coronary artery disease but is also commonly seen in patients with various forms of heart disease, including dilated, hypertrophic, and infiltrative cardiomyopathies. CMD can go unnoticed without any symptoms, or manifest as angina, and/or dyspnea, and contribute to the development of heart failure, and even sudden death especially when co-existing with myocardial fibrosis. However, whether CMD in non-ischemic cardiomyopathy is a cause or an effect of the underlying cardiomyopathic process, or whether it can be potentially modifiable with specific therapies, remains incompletely understood.
Literatur
1.
Zurück zum Zitat Gutterman DD, Chabowski DS, Kadlec AO, Durand MJ, Freed JK, Ait-Aissa K et al (2016) The human microcirculation: regulation of flow and beyond. Circ res 118:157–172CrossRefPubMedPubMedCentral Gutterman DD, Chabowski DS, Kadlec AO, Durand MJ, Freed JK, Ait-Aissa K et al (2016) The human microcirculation: regulation of flow and beyond. Circ res 118:157–172CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Spoladore R, Fisicaro A, Faccini A, Camici PG (2014) Coronary microvascular dysfunction in primary cardiomyopathies. Heart 100:806–813CrossRefPubMed Spoladore R, Fisicaro A, Faccini A, Camici PG (2014) Coronary microvascular dysfunction in primary cardiomyopathies. Heart 100:806–813CrossRefPubMed
3.
4.
Zurück zum Zitat Schwarz F, Mall G, Zebe H, Blickle J, Derks H, Manthey J et al (1983) Quantitative morphologic findings of the myocardium in idiopathic dilated cardiomyopathy. Am J Cardiol 51:501–506CrossRefPubMed Schwarz F, Mall G, Zebe H, Blickle J, Derks H, Manthey J et al (1983) Quantitative morphologic findings of the myocardium in idiopathic dilated cardiomyopathy. Am J Cardiol 51:501–506CrossRefPubMed
5.
Zurück zum Zitat Abraham D, Hofbauer R, Schafer R, Blumer R, Paulus P, Miksovsky A et al (2000) Selective downregulation of VEGF-A(165), VEGF-R(1), and decreased capillary density in patients with dilative but not ischemic cardiomyopathy. Circ res 87:644–647CrossRefPubMed Abraham D, Hofbauer R, Schafer R, Blumer R, Paulus P, Miksovsky A et al (2000) Selective downregulation of VEGF-A(165), VEGF-R(1), and decreased capillary density in patients with dilative but not ischemic cardiomyopathy. Circ res 87:644–647CrossRefPubMed
6.
Zurück zum Zitat Mosseri M, Schaper J, Admon D, Hasin Y, Gotsman MS, Sapoznikov D et al (1991) Coronary capillaries in patients with congestive cardiomyopathy or angina pectoris with patent main coronary arteries. Ultrastructural morphometry of endomyocardial biopsy samples. Circulation 84:203–210CrossRefPubMed Mosseri M, Schaper J, Admon D, Hasin Y, Gotsman MS, Sapoznikov D et al (1991) Coronary capillaries in patients with congestive cardiomyopathy or angina pectoris with patent main coronary arteries. Ultrastructural morphometry of endomyocardial biopsy samples. Circulation 84:203–210CrossRefPubMed
7.
Zurück zum Zitat Neglia D, Parodi O, Gallopin M, Sambuceti G, Giorgetti A, Pratali L et al (1995) Myocardial blood flow response to pacing tachycardia and to dipyridamole infusion in patients with dilated cardiomyopathy without overt heart failure. A quantitative assessment by positron emission tomography. Circulation 92:796–804CrossRefPubMed Neglia D, Parodi O, Gallopin M, Sambuceti G, Giorgetti A, Pratali L et al (1995) Myocardial blood flow response to pacing tachycardia and to dipyridamole infusion in patients with dilated cardiomyopathy without overt heart failure. A quantitative assessment by positron emission tomography. Circulation 92:796–804CrossRefPubMed
8.
Zurück zum Zitat Drzezga AE, Blasini R, Ziegler SI, Bengel FM, Picker W, Schwaiger M (2000) Coronary microvascular reactivity to sympathetic stimulation in patients with idiopathic dilated cardiomyopathy. J Nucl med 41:837–844PubMed Drzezga AE, Blasini R, Ziegler SI, Bengel FM, Picker W, Schwaiger M (2000) Coronary microvascular reactivity to sympathetic stimulation in patients with idiopathic dilated cardiomyopathy. J Nucl med 41:837–844PubMed
9.
Zurück zum Zitat Nowak B, Stellbrink C, Schaefer WM, Sinha AM, Breithardt OA, Kaiser HJ et al (2004) Comparison of regional myocardial blood flow and perfusion in dilated cardiomyopathy and left bundle branch block: role of wall thickening. J Nucl med 45:414–418PubMed Nowak B, Stellbrink C, Schaefer WM, Sinha AM, Breithardt OA, Kaiser HJ et al (2004) Comparison of regional myocardial blood flow and perfusion in dilated cardiomyopathy and left bundle branch block: role of wall thickening. J Nucl med 45:414–418PubMed
10.
Zurück zum Zitat Ono S, Nohara R, Kambara H, Okuda K, Kawai C (1992) Regional myocardial perfusion and glucose metabolism in experimental left bundle branch block. Circulation 85:1125–1131CrossRefPubMed Ono S, Nohara R, Kambara H, Okuda K, Kawai C (1992) Regional myocardial perfusion and glucose metabolism in experimental left bundle branch block. Circulation 85:1125–1131CrossRefPubMed
11.
Zurück zum Zitat Masci PG, Marinelli M, Piacenti M, Lorenzoni V, Positano V, Lombardi M et al (2010) Myocardial structural, perfusion, and metabolic correlates of left bundle branch block mechanical derangement in patients with dilated cardiomyopathy: a tagged cardiac magnetic resonance and positron emission tomography study. Circ Cardiovasc Imaging 3:482–490CrossRefPubMed Masci PG, Marinelli M, Piacenti M, Lorenzoni V, Positano V, Lombardi M et al (2010) Myocardial structural, perfusion, and metabolic correlates of left bundle branch block mechanical derangement in patients with dilated cardiomyopathy: a tagged cardiac magnetic resonance and positron emission tomography study. Circ Cardiovasc Imaging 3:482–490CrossRefPubMed
12.
Zurück zum Zitat Majmudar MD, Murthy VL, Shah RV, Kolli S, Mousavi N, Foster CR et al (2015) Quantification of coronary flow reserve in patients with ischaemic and non-ischaemic cardiomyopathy and its association with clinical outcomes. Eur Heart J Cardiovasc Imaging 16:900–909CrossRefPubMedPubMedCentral Majmudar MD, Murthy VL, Shah RV, Kolli S, Mousavi N, Foster CR et al (2015) Quantification of coronary flow reserve in patients with ischaemic and non-ischaemic cardiomyopathy and its association with clinical outcomes. Eur Heart J Cardiovasc Imaging 16:900–909CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Nikolaidis LA, Doverspike A, Huerbin R, Hentosz T, Shannon RP (2002) Angiotensin-converting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin-mediated, nitric oxide-dependent mechanism. Circulation 105:2785–2790CrossRefPubMed Nikolaidis LA, Doverspike A, Huerbin R, Hentosz T, Shannon RP (2002) Angiotensin-converting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin-mediated, nitric oxide-dependent mechanism. Circulation 105:2785–2790CrossRefPubMed
14.
Zurück zum Zitat Sugioka K, Hozumi T, Takemoto Y, Ujino K, Matsumura Y, Watanabe H et al (2005) Early recovery of impaired coronary flow reserve by carvedilol therapy in patients with idiopathic dilated cardiomyopathy: a serial transthoracic Doppler echocardiographic study. J am Coll Cardiol 45:318–319CrossRefPubMed Sugioka K, Hozumi T, Takemoto Y, Ujino K, Matsumura Y, Watanabe H et al (2005) Early recovery of impaired coronary flow reserve by carvedilol therapy in patients with idiopathic dilated cardiomyopathy: a serial transthoracic Doppler echocardiographic study. J am Coll Cardiol 45:318–319CrossRefPubMed
15.
Zurück zum Zitat Knaapen P, van Campen LM, de Cock CC, Gotte MJ, Visser CA, Lammertsma AA et al (2004) Effects of cardiac resynchronization therapy on myocardial perfusion reserve. Circulation 110:646–651CrossRefPubMed Knaapen P, van Campen LM, de Cock CC, Gotte MJ, Visser CA, Lammertsma AA et al (2004) Effects of cardiac resynchronization therapy on myocardial perfusion reserve. Circulation 110:646–651CrossRefPubMed
16.
Zurück zum Zitat Dilsizian V, Bonow RO, Epstein SE, Fananapazir L (1993) Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J am Coll Cardiol 22:796–804CrossRefPubMed Dilsizian V, Bonow RO, Epstein SE, Fananapazir L (1993) Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J am Coll Cardiol 22:796–804CrossRefPubMed
17.
Zurück zum Zitat Knaapen P, Germans T, Camici PG, Rimoldi OE, ten Cate FJ, ten Berg JM et al (2008) Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 294:H986–H993CrossRefPubMed Knaapen P, Germans T, Camici PG, Rimoldi OE, ten Cate FJ, ten Berg JM et al (2008) Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 294:H986–H993CrossRefPubMed
18.
Zurück zum Zitat Tanaka M, Fujiwara H, Onodera T, Wu DJ, Matsuda M, Hamashima Y et al (1987) Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation 75:1130–1139CrossRefPubMed Tanaka M, Fujiwara H, Onodera T, Wu DJ, Matsuda M, Hamashima Y et al (1987) Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation 75:1130–1139CrossRefPubMed
19.
Zurück zum Zitat Maron BJ, Wolfson JK, Epstein SE, Roberts WC (1986) Intramural (“small vessel”) coronary artery disease in hypertrophic cardiomyopathy. J am Coll Cardiol 8:545–557CrossRefPubMed Maron BJ, Wolfson JK, Epstein SE, Roberts WC (1986) Intramural (“small vessel”) coronary artery disease in hypertrophic cardiomyopathy. J am Coll Cardiol 8:545–557CrossRefPubMed
20.
Zurück zum Zitat Timmer SA, Germans T, Brouwer WP, Lubberink M, van der Velden J, Wilde AA et al (2011) Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction. Eur J Heart Fail 13:1283–1289CrossRefPubMed Timmer SA, Germans T, Brouwer WP, Lubberink M, van der Velden J, Wilde AA et al (2011) Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction. Eur J Heart Fail 13:1283–1289CrossRefPubMed
21.
Zurück zum Zitat Bravo PE, Pinheiro A, Higuchi T, Rischpler C, Merrill J, Santaularia-Tomas M et al (2012) PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 53:407–414CrossRef Bravo PE, Pinheiro A, Higuchi T, Rischpler C, Merrill J, Santaularia-Tomas M et al (2012) PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 53:407–414CrossRef
22.
Zurück zum Zitat Olivotto I, Girolami F, Sciagra R, Ackerman MJ, Sotgia B, Bos JM et al (2011) Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J am Coll Cardiol 58:839–848CrossRefPubMed Olivotto I, Girolami F, Sciagra R, Ackerman MJ, Sotgia B, Bos JM et al (2011) Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J am Coll Cardiol 58:839–848CrossRefPubMed
23.
Zurück zum Zitat Petersen SE, Jerosch-Herold M, Hudsmith LE, Robson MD, Francis JM, Doll HA et al (2007) Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation 115:2418–2425CrossRefPubMed Petersen SE, Jerosch-Herold M, Hudsmith LE, Robson MD, Francis JM, Doll HA et al (2007) Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation 115:2418–2425CrossRefPubMed
24.
Zurück zum Zitat Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ (2000) Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 84:476–482CrossRefPubMedPubMedCentral Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ (2000) Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 84:476–482CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Krams R, Kofflard MJ, Duncker DJ, Von Birgelen C, Carlier S, Kliffen M et al (1998) Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation 97:230–233CrossRefPubMed Krams R, Kofflard MJ, Duncker DJ, Von Birgelen C, Carlier S, Kliffen M et al (1998) Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation 97:230–233CrossRefPubMed
26.
Zurück zum Zitat Camici P, Chiriatti G, Lorenzoni R, Bellina RC, Gistri R, Italiani G et al (1991) Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. J am Coll Cardiol 17:879–886CrossRefPubMed Camici P, Chiriatti G, Lorenzoni R, Bellina RC, Gistri R, Italiani G et al (1991) Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. J am Coll Cardiol 17:879–886CrossRefPubMed
27.
Zurück zum Zitat Sotgia B, Sciagra R, Olivotto I, Casolo G, Rega L, Betti I et al (2008) Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 49:1090–1096CrossRef Sotgia B, Sciagra R, Olivotto I, Casolo G, Rega L, Betti I et al (2008) Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 49:1090–1096CrossRef
28.
Zurück zum Zitat Bravo PE, Zimmerman SL, Luo HC, Pozios I, Rajaram M, Pinheiro A et al (2013) Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy. Circulation Cardiovascular Imaging 6:210–217CrossRefPubMedPubMedCentral Bravo PE, Zimmerman SL, Luo HC, Pozios I, Rajaram M, Pinheiro A et al (2013) Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy. Circulation Cardiovascular Imaging 6:210–217CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG (2003) Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J med 349:1027–1035CrossRefPubMed Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG (2003) Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J med 349:1027–1035CrossRefPubMed
30.
Zurück zum Zitat Olivotto I, Cecchi F, Gistri R, Lorenzoni R, Chiriatti G, Girolami F et al (2006) Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J am Coll Cardiol 47:1043–1048CrossRefPubMed Olivotto I, Cecchi F, Gistri R, Lorenzoni R, Chiriatti G, Girolami F et al (2006) Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J am Coll Cardiol 47:1043–1048CrossRefPubMed
31.
Zurück zum Zitat Marian AJ (2016) Challenges in the diagnosis of Anderson-Fabry disease: a deceptively simple and yet complicated genetic disease. J am Coll Cardiol 68:1051–1053CrossRefPubMed Marian AJ (2016) Challenges in the diagnosis of Anderson-Fabry disease: a deceptively simple and yet complicated genetic disease. J am Coll Cardiol 68:1051–1053CrossRefPubMed
33.
Zurück zum Zitat Tomberli B, Cecchi F, Sciagra R, Berti V, Lisi F, Torricelli F et al (2013) Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease. Eur J Heart Fail 15:1363–1373CrossRefPubMed Tomberli B, Cecchi F, Sciagra R, Berti V, Lisi F, Torricelli F et al (2013) Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease. Eur J Heart Fail 15:1363–1373CrossRefPubMed
35.
Zurück zum Zitat Kovarnik T, Mintz GS, Karetova D, Horak J, Bultas J, Skulec R et al (2008) Intravascular ultrasound assessment of coronary artery involvement in Fabry disease. J Inherit Metab dis 31:753–760CrossRefPubMed Kovarnik T, Mintz GS, Karetova D, Horak J, Bultas J, Skulec R et al (2008) Intravascular ultrasound assessment of coronary artery involvement in Fabry disease. J Inherit Metab dis 31:753–760CrossRefPubMed
36.
Zurück zum Zitat Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A et al (2007) Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 28:1228–1235CrossRefPubMed Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A et al (2007) Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 28:1228–1235CrossRefPubMed
37.
Zurück zum Zitat Kalliokoski RJ, Kalliokoski KK, Sundell J, Engblom E, Penttinen M, Kantola I et al (2005) Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease. J Inherit Metab dis 28:563–573CrossRefPubMed Kalliokoski RJ, Kalliokoski KK, Sundell J, Engblom E, Penttinen M, Kantola I et al (2005) Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease. J Inherit Metab dis 28:563–573CrossRefPubMed
38.
Zurück zum Zitat Elliott PM, Kindler H, Shah JS, Sachdev B, Rimoldi OE, Thaman R et al (2006) Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 92:357–360CrossRefPubMed Elliott PM, Kindler H, Shah JS, Sachdev B, Rimoldi OE, Thaman R et al (2006) Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 92:357–360CrossRefPubMed
39.
Zurück zum Zitat Kalliokoski RJ, Kantola I, Kalliokoski KK, Engblom E, Sundell J, Hannukainen JC et al (2006) The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. J Inherit Metab dis 29:112–118CrossRefPubMed Kalliokoski RJ, Kantola I, Kalliokoski KK, Engblom E, Sundell J, Hannukainen JC et al (2006) The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. J Inherit Metab dis 29:112–118CrossRefPubMed
40.
Zurück zum Zitat Koskenvuo JW, Hartiala JJ, Nuutila P, Kalliokoski R, Viikari JS, Engblom E et al (2008) Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters. J Inherit Metab dis 31:432–441CrossRefPubMed Koskenvuo JW, Hartiala JJ, Nuutila P, Kalliokoski R, Viikari JS, Engblom E et al (2008) Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters. J Inherit Metab dis 31:432–441CrossRefPubMed
41.
Zurück zum Zitat Falk RH, Alexander KM, Liao R, Dorbala S (2016) AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J am Coll Cardiol 68:1323–1341CrossRefPubMed Falk RH, Alexander KM, Liao R, Dorbala S (2016) AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J am Coll Cardiol 68:1323–1341CrossRefPubMed
42.
Zurück zum Zitat Al Suwaidi J, Velianou JL, Gertz MA, Cannon RO 3rd, Higano ST, Holmes DR Jr et al (1999) Systemic amyloidosis presenting with angina pectoris. Ann Intern med 131:838–841CrossRefPubMed Al Suwaidi J, Velianou JL, Gertz MA, Cannon RO 3rd, Higano ST, Holmes DR Jr et al (1999) Systemic amyloidosis presenting with angina pectoris. Ann Intern med 131:838–841CrossRefPubMed
43.
Zurück zum Zitat Dorbala S, Vangala D, Bruyere J Jr, Quarta C, Kruger J, Padera R et al (2014) Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail 2:358–367CrossRefPubMedPubMedCentral Dorbala S, Vangala D, Bruyere J Jr, Quarta C, Kruger J, Padera R et al (2014) Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail 2:358–367CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Neben-Wittich MA, Wittich CM, Mueller PS, Larson DR, Gertz MA, Edwards WD (2005) Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis. Am J med 118:1287CrossRefPubMed Neben-Wittich MA, Wittich CM, Mueller PS, Larson DR, Gertz MA, Edwards WD (2005) Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis. Am J med 118:1287CrossRefPubMed
45.
Zurück zum Zitat Modesto KM, Dispenzieri A, Gertz M, Cauduro SA, Khandheria BK, Seward JB et al (2007) Vascular abnormalities in primary amyloidosis. Eur Heart J 28:1019–1024CrossRefPubMed Modesto KM, Dispenzieri A, Gertz M, Cauduro SA, Khandheria BK, Seward JB et al (2007) Vascular abnormalities in primary amyloidosis. Eur Heart J 28:1019–1024CrossRefPubMed
46.
Zurück zum Zitat Migrino RQ, Truran S, Gutterman DD, Franco DA, Bright M, Schlundt B et al (2011) Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. Am J Physiol Heart Circ Physiol 301:H2305–H2312CrossRefPubMedPubMedCentral Migrino RQ, Truran S, Gutterman DD, Franco DA, Bright M, Schlundt B et al (2011) Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. Am J Physiol Heart Circ Physiol 301:H2305–H2312CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Dorbala S, Vangala D, Bruyere J Jr, Quarta C, Kruger J, Padera R et al (2014) Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Failure Dorbala S, Vangala D, Bruyere J Jr, Quarta C, Kruger J, Padera R et al (2014) Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Failure
48.
Zurück zum Zitat van den Heuvel AF, van Veldhuisen DJ, van der Wall EE, Blanksma PK, Siebelink HM, Vaalburg WM et al (2000) Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J am Coll Cardiol 35:19–28CrossRefPubMed van den Heuvel AF, van Veldhuisen DJ, van der Wall EE, Blanksma PK, Siebelink HM, Vaalburg WM et al (2000) Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J am Coll Cardiol 35:19–28CrossRefPubMed
49.
Zurück zum Zitat Range FT, Paul M, Schafers KP, Acil T, Kies P, Hermann S et al (2009) Myocardial perfusion in nonischemic dilated cardiomyopathy with and without atrial fibrillation. J Nucl med 50:390–396CrossRefPubMed Range FT, Paul M, Schafers KP, Acil T, Kies P, Hermann S et al (2009) Myocardial perfusion in nonischemic dilated cardiomyopathy with and without atrial fibrillation. J Nucl med 50:390–396CrossRefPubMed
Metadaten
Titel
Role of PET to evaluate coronary microvascular dysfunction in non-ischemic cardiomyopathies
verfasst von
Paco E. Bravo
Marcelo F. Di Carli
Sharmila Dorbala
Publikationsdatum
03.06.2017
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 4/2017
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-017-9628-1

Weitere Artikel der Ausgabe 4/2017

Heart Failure Reviews 4/2017 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.